Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| Altimmune to Announce First Quarter 2021 Financial Results on May 17, 2021 | ||||||||||||||||||||||
| By: GlobeNewswire - 11 May 2021 | Back to overview list |
|||||||||||||||||||||
GAITHERSBURG, Md., May 11, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2021 financial results on Monday, May 17, 2021. Altimmune management will host a conference call for investors beginning at 8:30 am E.T. to discuss the first quarter 2021 financial results and provide a business update. Conference Call Information:
About Altimmune Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com. Follow @Altimmune, Inc. on LinkedIn Investor & Media Contacts:
|
||||||||||||||||||||||
|
||||||||||||||||||||||
 | Back to overview list | |||||||||||||||||||||